Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.